Jazz Pharmaceuticals (JAZZ) PT Raised to $280 at Baird
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $242.03 +0.54%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 25
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 25
Join SI Premium – FREE
Baird analyst Brian Skorney raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $280.00 (from $252.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Teradata (TDC) PT Lowered to $32 at UBS on Cautious Q3 View
- Xcel Energy (XEL) PT Lowered to $83 at Morgan Stanley
- Wix.com (WIX) PT Raised to $75 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
